3,4-diaminopyridine (DrugBank: -)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 11 | 重症筋無力症 | 5 |
| 12 | 先天性筋無力症候群 | 3 |
| 13 | 多発性硬化症／視神経脊髄炎 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JMA-IIA00208 | 01/12/2017 | 10/03/2015 | Efficacy of 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenia syndrome | Efficacy of 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenia syndrome | Lambert-Eaton myasthenia syndrome | Intervention type:DRUG. Intervention1:3,4-diaminopyridine, Dose form:POWDER, Route of administration:ORAL. Control intervention1:placebo, Dose form:POWDER, Route of administration:ORAL. | Hiroyuki FUKUDA | NULL | Completed | No Limit | No Limit | BOTH | 3 | NOT APPLICABLE | Japan |
| 2 | NCT03062631 (ClinicalTrials.gov) | February 20, 2017 | 21/2/2017 | Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome | Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome | Congenital Myasthenic Syndrome;Lambert-Eaton Myasthenic Syndrome | Drug: 3,4-Diaminopyridine | Ricardo Maselli | Jacobus Pharmaceutical | Available | 3 Months | 75 Years | All | United States | ||
| 3 | EUCTR2015-003127-62-IT (EUCTR) | 02/10/2015 | 17/03/2017 | A Randomized, Placebo-Controlled Study to Evaluate the Effect of Amifampridine in Patients with MuSK Antibody Positive Myasthenia Gravis | A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate(3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis - MuSK-001 | Patients with MuSK Antibody Positive Myasthenia Gravis MedDRA version: 19.1;Level: LLT;Classification code 10062976;Term: Neuromuscular weakness;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Product Name: AMIFAMPRIDINA INN or Proposed INN: AMIFAMPRIDINA | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Italy | ||
| 4 | NCT02012933 (ClinicalTrials.gov) | December 2011 | 11/12/2013 | 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) | 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia | Lambert-Eaton Myasthenic Syndrome (LEMS);Congenital Myasthenia (CM) | Drug: 3,4-diaminopyridine | Oregon Health and Science University | Jacobus Pharmaceutical | No longer available | 2 Years | N/A | All | United States | ||
| 5 | EUCTR2010-021850-20-IT (EUCTR) | 23/11/2011 | 07/03/2012 | A Phase 3 placebo controlled study to evaluate safety and efficacy of Amifampridine phosphate. | A Phase 3, Multicenter, Double-blind, Placebo-controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS) | Lambert-Eaton Myasthenic Syndrome (LEMS) MedDRA version: 14.1;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | Trade Name: FIRDAPSE 10mg Tablets INN or Proposed INN: AMIFAMPRIDINE Other descriptive name: 3,4-DAP | BIOMARIN PHARMACEUTICAL INC. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | United States;Hungary;Spain;Bulgaria;Germany;Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03062631 (ClinicalTrials.gov) | February 20, 2017 | 21/2/2017 | Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome | Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome | Congenital Myasthenic Syndrome;Lambert-Eaton Myasthenic Syndrome | Drug: 3,4-Diaminopyridine | Ricardo Maselli | Jacobus Pharmaceutical | Available | 3 Months | 75 Years | All | United States | ||
| 2 | NCT01765140 (ClinicalTrials.gov) | January 2012 | 6/1/2013 | Treatment Use of 3,4-Diaminopyridine | Treatment Use of 3,4-Diaminopyridine in Congenital Myasthenic Syndrome | Myasthenic Syndromes, Congenital | Drug: 3,4-diaminopyridine | Vern C. Juel, M.D. | NULL | No longer available | N/A | N/A | All | United States | ||
| 3 | NCT00872950 (ClinicalTrials.gov) | June 2001 | 30/3/2009 | 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) | Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS) | Lambert-Eaton Myasthenic Syndrome;Congenital Myasthenic Syndrome | Drug: 3,4-DIAMINOPYRIDINE | Lahey Clinic | NULL | Active, not recruiting | 18 Years | N/A | All | 22 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00342381 (ClinicalTrials.gov) | June 2006 | 20/6/2006 | Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation | Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation | Multiple Sclerosis;Fatigue | Drug: 3,4-diaminopyridine;Drug: Placebo | University of Aarhus | The Danish Multiple Sclerosis Society | Completed | 18 Years | 55 Years | Both | 120 | Phase 2 | Denmark |
| 2 | NCT00190268 (ClinicalTrials.gov) | February 2005 | 13/9/2005 | Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis | Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis | Multiple Sclerosis | Drug: 3,4-diaminopyridine | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 60 Years | Both | 126 | Phase 3 | France |